Neurodegenerative diseases are an increasing public concern, being currently the eighth cause of disease burden for developed regions. During the last years, several studies have showed the potential of the endocannabinoid system on neurodegenerative diseases, however these studies do not offer a complete understanding of the mechanisms involved and the possible application of cannabinoids for the therapeutic treatment of these diseases. Our goals in this project are the development of: i) CB1 antagonists, with antioxidant properties, for the treatment of Parkinson’s disease. ii) CB2 agonists and molecules with dual action (cannabinoid and cholinergic properties) for the treatment of Alzheimer’s disease.
Neurodegenerative diseases
